Actinium Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Actinium Pharmaceuticals, Inc. on March 9, 2018, covering events that occurred on March 6 and March 9, 2018. The filing details the completion of a previously announced rights offering.
Key Financial Metrics
The company raised capital through the sale of units in the Rights Offering. Key figures include:
- Gross Proceeds: Approximately $15.1 million.
- Net Proceeds: Approximately $13.9 million (after deducting dealer-manager fees and expenses).
- Units Sold: 30,125,326 units.
- Components: 30,125,326 shares of common stock, 7,531,304 Series A warrants, and 22,593,967 Series B warrants.
- Warrant Exercise Prices: $0.60 per share for Series A; $0.70 per share for Series B.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels, as this report focuses solely on the capital raise event.
Material Changes
The primary material change is the increase in equity capital and the issuance of new shares and warrants. The company successfully completed the offering pursuant to its effective registration statement on Form S-3 (No. 333-216748).
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation of the offering's completion. The filing notes that the net proceeds exclude any future proceeds that may be received upon the exercise of the warrants. No specific guidance, risks, or contingencies beyond the standard completion of the offering are detailed in this specific text.
Investor Verification Checklist
- Verify the final number of shares outstanding post-offering to assess dilution.
- Confirm the specific use of the $13.9 million in net proceeds as outlined in the original prospectus.
- Review the terms of the Series A and Series B warrants for expiration dates and exercise conditions.
- Check subsequent filings for any updates on the company's cash position and runway following this capital raise.